Hanwha In Talks For Enbrel Biosimilar Deal
This article was originally published in PharmAsia News
Executive Summary
Germany’s Merck is one of the multinationals said to be in negotiations with the South Korean firm Hanwha over the possible licensing of a biosimilar version of Amgen’s blockbuster rheumatoid arthritis treatment Enbrel and/or related technology.